Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
FibroBiologics, Inc. ( (FBLG) ) has issued an update.
On July 1, 2025, FibroBiologics, Inc. received a notification from Nasdaq indicating that its stock had fallen below the minimum bid price required for continued listing. The company has until December 29, 2025, to regain compliance by ensuring the stock price is at least $1.00 for ten consecutive days. If compliance is not achieved, FibroBiologics may face delisting but can appeal or seek an additional compliance period.
The most recent analyst rating on (FBLG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.
Spark’s Take on FBLG Stock
According to Spark, TipRanks’ AI Analyst, FBLG is a Underperform.
FibroBiologics, Inc. is in a challenging position typical for early-stage biotech firms. The company’s financials indicate ongoing losses and reliance on external financing, which is a major risk factor. Technical indicators suggest slight momentum but also highlight resistance levels due to its price position below key moving averages. The valuation reflects the unprofitable nature of the firm with no dividend to attract income-focused investors. These factors combined result in a low stock score, emphasizing the company’s need for a clear path to revenue generation.
To see Spark’s full report on FBLG stock, click here.
More about FibroBiologics, Inc.
Average Trading Volume: 322,787
Technical Sentiment Signal: Sell
Current Market Cap: $22.98M
Learn more about FBLG stock on TipRanks’ Stock Analysis page.